MedTrace Logo

The ePass Clinical Trial for the Treatment of Obese Subjects

NCT02954016 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-11-03

No results posted yet for this study

Summary

To evaluate the safety and efficacy of the endoscopically implanted ValenTx EndoPass™ System for treatment of adults with severe obesity.

The EndoPass System is indicated for weight loss in adults with a body mass index (BMI) ≥35 and ≤ 50 kg/m2 who have failed more conservative weight loss methods.

Conditions

Interventions

DEVICE

ePass

Subject is implanted with the device for up to 3 years.

Sponsors & Collaborators

  • ValenTx, Inc.

    lead INDUSTRY

Principal Investigators

  • Roland Maude-Griffin · ValenTx, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2021-03-31
Completion
2022-03-31

Countries

  • Argentina
  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02954016 on ClinicalTrials.gov